Clinical trials
Leukemia, Myeloid clinical trials
Below are recruiting leukemia, myeloid clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06262438RecruitingPhase 2
Quizartinib plus chemo for children with FLT3-ITD AML
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
Utrecht, UtrechtAges 1 month–18 years - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT06580106Recruiting
Genes, side effects, and response to azacitidine and venetoclax in AML
This study looks at how genes affect the response to a combination of two drugs (azacitidine and venetoclax) in people with AML. It aims to understand why some people have side effects and how well the treatment works.
Charlotte, North CarolinaAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06557421RecruitingPhase 2
Stopping venetoclax and azacitidine in AML remission
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
MarseilleAges 18 years+ - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT06510868Recruiting
MDS risk study for NET patients before or after PRRT
This study looks at the risk of developing Myelodysplastic Syndrome (MDS), a blood disorder, in people with Neuroendocrine Tumors (NET) who are treated with Peptide Radionuclide Therapy (PRRT). It involves a simple blood test to check for genetic changes linked to MDS. Participating can help understand and potentially prevent this side effect.
Toronto, OntarioAges Any age - NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06451861RecruitingPhase 2
Testing a new drug combo for newly diagnosed AML
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
Dongguan, GuangdongAges 18 years+ - NCT06423911RecruitingPhase 3
Study of olverembatinib for people with chronic phase CML
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
Birmingham, AlabamaAges 18 years+ - NCT06424340RecruitingPhase 1/Phase 2
Cell therapy for relapsed or refractory AML with NPM1 mutation
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
LeidenAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06220162RecruitingPhase 2
VAC Regimen for AML Not Responding to VA
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
Suzhou, JiangsuAges 18–80 - NCT06191263RecruitingPhase 2
RVU120 plus venetoclax for relapsed AML
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
GrenobleAges 18 years+ - NCT04986657Recruiting
Whole genome testing to help diagnose AML or MDS
This study checks whether adding whole genome sequencing (reading a person’s DNA more broadly) alongside standard genetic tests improves the diagnosis process for AML or MDS. It may help doctors decide on the best next steps when AML/MDS is suspected.
St Louis, MissouriAges 18 years+ - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70
Hear when a new Leukemia, Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, myeloid?
- Yes. Clin2 currently lists 575 recruiting leukemia, myeloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.